Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Dow
Mallinckrodt
McKinsey
Express Scripts
Boehringer Ingelheim
Baxter

Last Updated: January 17, 2020

DrugPatentWatch Database Preview

Aspen Company Profile

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Summary for Aspen
International Patents:17
US Patents:2
Tradenames:11
Ingredients:12
NDAs:14

Drugs and US Patents for Aspen

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Aspen ENJUVIA estrogens, conjugated synthetic b TABLET;ORAL 021443-003 May 10, 2004 DISCN No No 6,660,726   Start Trial Y Y   Start Trial
Aspen ENJUVIA estrogens, conjugated synthetic b TABLET;ORAL 021443-004 May 10, 2004 DISCN No No 6,660,726   Start Trial Y Y   Start Trial
Aspen Global Inc HYDROXYPROGESTERONE CAPROATE hydroxyprogesterone caproate SOLUTION;INTRAMUSCULAR 200271-001 Aug 24, 2015 RX No Yes   Start Trial   Start Trial
Aspen Global Inc THIOGUANINE thioguanine TABLET;ORAL 012429-001 Approved Prior to Jan 1, 1982 RX Yes Yes   Start Trial   Start Trial
Aspen Global Inc DECA-DURABOLIN nandrolone decanoate INJECTABLE;INJECTION 013132-002 Jun 12, 1986 DISCN No No   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for Aspen

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Aspen CENESTIN estrogens, conjugated synthetic a TABLET;ORAL 020992-004 Mar 13, 2000 5,908,638   Start Trial
Aspen CENESTIN estrogens, conjugated synthetic a TABLET;ORAL 020992-001 Jun 21, 2002 5,908,638   Start Trial
Aspen Global Inc CYCLESSA desogestrel; ethinyl estradiol TABLET;ORAL-28 021090-001 Dec 20, 2000 4,616,006   Start Trial
Aspen CENESTIN estrogens, conjugated synthetic a TABLET;ORAL 020992-005 Feb 5, 2004 5,908,638   Start Trial
Aspen Global Inc ORGARAN danaparoid sodium INJECTABLE;INJECTION 020430-001 Dec 24, 1996 5,164,377   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Paragraph IV (Patent) Challenges for ASPEN drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Tablets 0.625 mg ➤ Subscribe 2009-03-02
➤ Subscribe Tablets 1.25 mg ➤ Subscribe 2008-11-03
➤ Subscribe Tablets 0.3 mg, 0.45 mg and 0.9 mg ➤ Subscribe 2009-03-19
Premature patent expirations for ASPEN

Expiration due to failure to pay maintenance fee

Patent Number Expiration Date
  Start Trial   Start Trial

Supplementary Protection Certificates for Aspen Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1429780 13C0012 France   Start Trial PRODUCT NAME: COMBINAISON DE CIPROFLOXACINE ET DE DEXAMETHASONE, EN PARTICULIER DE CHLORHYDRATE DE CIPROFLOXACINE ET DE DEXAMETHASONE; NAT. REGISTRATION NO/DATE: NL 41308 20121214; FIRST REGISTRATION: 48976 20120808
1429780 SPC/GB12/058 United Kingdom   Start Trial PRODUCT NAME: A COMBINATION OF CIPROFLOXACIN AND DEXAMETHASONE, PREFERABLY CIPROFLOXACIN HYDROCHLORIDE AND DEXAMETHASONE; REGISTERED: DK DE/11/3337/001/DC 20120808; UK PL000649/0381-0001 20121003
1581193 SPC/GB12/047 United Kingdom   Start Trial PRODUCT NAME: DEXAMETHASONE; REGISTERED: UK EU/1/10/638/001 20100727
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Moodys
Medtronic
Baxter
Harvard Business School
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.